Stanislaw R. Burzynski et al., 2006-03: Burzynski's own phase 2 report on 18 evaluable patients with high-grade, recurrent and progressive brainstem glioma treated with antineoplastons A10 and AS2-1: complete response 11%, partial response 11%, stable disease 39%, progressive disease 39%.
Complete response was achieved in 11%, partial response in 11%, stable disease in 39%, and progressive disease in 39% of patients.
Results (article pp. 40-47)
Stanislaw R. Burzynski et al., 2006-03: Burzynski's own phase 2 report on 18 evaluable patients with high-grade, recurrent and progressive brainstem glioma treated with antineoplastons A10 and AS2-1: complete response 11%, partial response 11%, stable disease 39%, progressive disease 39%. Funder/conflicts: authors are Burzynski Clinic/BRI personnel; the paper reports no external funding and no independent sponsor. Maker: BRI manufactured the antineoplastons. Comparator: none – single-arm, pooled across four protocols, with historical survival figures cited rather than a control group. Authors concede 'a larger study is required to confirm these results'; no phase 3 was ever completed. Read with CHF-16, whose audit found response misclassification in the same programme. Burzynski's side is recorded here in his own words. Study type: uncontrolled series.
